Hormonal
Obesity-induced chronic low-grade inflammation in adipose tissue, driven by immune cell infiltration and pro-inflammatory cytokine secretion (TNF-α, IL-6, IL-1β), directly causes insulin resistance by disrupting insulin signaling cascades in metabolic tissues.
Focus on reducing systemic inflammation through diet, not just weight loss. The paper highlights that obesity creates an inflammatory environment in fat tissue that directly blocks insulin action. Nutritional strategies that reduce this inflammation (e.g., anti-inflammatory nutrients) may help improve insulin sensitivity independently of or alongside weight management.
Obesity and associated chronic inflammation initiate a state of insulin resistance (IR). The secretion of chemoattractants such as MCP-1 and MIF and of cytokines IL-6, TNF-α, and IL-1β, draw immune cells including dendritic cells, T cells, and macrophages into adipose tissue (AT)... A feedback loop of pro-inflammatory cytokines exacerbates this pathological state, driving infiltration and cytokine secretion and disrupts the insulin signaling cascade.
Why this rating
This is a review article synthesizing multiple mechanistic studies; while not a primary clinical trial, the mechanistic consensus is strong.
Source
Mechanisms of Obesity-Induced Inflammation and Insulin Resistance: Insights into the Emerging Role of Nutritional Strategies
Maeve A. McArdle et al. · Frontiers in Endocrinology · 2013
DOI 10.3389/fendo.2013.00052
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →